The strong correlation of the presence of DDR gene mutations with poor survival in this study raises the possibility that NGS-guided treatment with PARP inhibitors in HNSCC might lead to improvement in survival in select patients. The gene discussed is PARP1; the disease is head and neck squamous cell carcinoma.